A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

NCT00642538 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: MKC253 Inhalation Powder
DRUG: Technosphere Inhalation Powder
DRUG: subcutaneous injection

Sponsor

Mannkind Corporation